Inhibition of Lymphocyte-Mediated Cytolysis and Cyclic amp Phosphodiesterase by Erythro-9–(2-Hydroxy-3-Nonyl)Adenine

References

• Schaeffer H. J., Schwender C. F. Enzyme inhibitors. 26. Bridging hydrophobic and hydrophilic regions on adenosine deaminase with some 9-(2-hydroxy-3-alkyl)adenines. J. Med. Chem. 1974; 17: 6
   PubMed Web of Science ®Google Scholar
• Glazer R. I. Adenosine deaminase inhibitors: Their role in chemotherapy and immunosuppression. Cancer Chemother. Pharmacol. 1980; 4: 227
   PubMed Web of Science ®Google Scholar
• Shannon W. M., Schabel F. M., Jr. Antiviral agents as adjuncts in cancer chemotherapy. Pharmac. Ther. 1980; 11: 263
   PubMed Web of Science ®Google Scholar
• Lum C. T., Sutherland D. E.R., Najarian J. S. Inhibition for immunosuppression. N. Engl. J. Med. 1977; 296: 819
   PubMedGoogle Scholar
• Lum C. T., Sutherland D. E.R., Payne W. D., Gorecki P., Matas A. J., Najarian J. S. Prolongation of mouse and rat pancreatic islet cell allografts by adenosine deaminase inhibitors and adenine arabinoside. J. Surg. Res. 1980; 28: 44
   PubMedGoogle Scholar
• Adamson R. H., Chassin M. M., Chirigos M. A., Johns D. G. Modes of Action: Some aspects of the pharmacology of the adenosine deaminase inhibitors 2′-deoxycoformycin and erythro-9-(2-hydroxy-3-nonyl)adenine. in Current Chemotherapy. Proc. of 10th International Congress of Chemotherapy, W. Siegenthaler, R. Luthy. American Society for Microbiology, Washington, DC 1978; Vol. 11: 1116
   Google Scholar
• North T. W., Cohen S. S. Erythro-9-(2-hydroxy-3-nonyl)-adenine as a specific inhibitor of herpes simplex virus replication in the presence and absence of adenosine analogues. Proc. Natl. Acad. Sci. 1978; 75: 4684
   PubMedGoogle Scholar
• Shannon W. M., Arnett G., Schabel F. M., Jr., North T. W., Cohen S. S. Erythro-9-(2-hydroxy-3-nonyl)adenine alone and in combination with 9–β-D-arabinofuranosyladenine in treatment of systemic herpesvirus infections in mice. Antimicrob. Agents Chemother. 1980; 18: 598
   PubMedGoogle Scholar
• Carson D. A., Seegmiller J. E. Effect of adenosine deaminase inhibition upon human lymphocyte blastogenesis. J. Clin. Invest. 1976; 57: 274
   PubMedGoogle Scholar
• Hirschhorn R., Sela E. Adenosine deaminase and immunodeficiency: An in vitro model. Cell. Immunol. 1977; 32: 350
   PubMedGoogle Scholar
• Lum C. T., Sutherland D. E., Najarian J. S. Inhibition of PHA and NaIO4 mitogenesis by the adenosine deaminase inhibitors erythro-9-(2-hydroxy-3-nonyl)adenine (EHNA) and 2′-deoxycoformycin (2-dCF). Clin. Immunol. and Immunopath. 1979; 12: 453
   PubMedGoogle Scholar
• Ballow M., Pantschenko A. Effect of ADA inhibitors on murine lymphocyte subpopulations. Fed. Proc. Fed. Am. Soc. Exp. Biol. 1981; 40: 1081
   Google Scholar
• Fischer D., Van der Weyden M. B., Snyderman R., Kelley W. N. A role for adenosine deaminase in human monocyte maturation. J. Clin. Invest. 1976; 58: 399
   PubMed Web of Science ®Google Scholar
• Lum C. T., Schmidtke J. R., Sutherland D. E., Najarian J. S. Inhibition of human T-cell rosette formation by the adenosine deaminase inhibitor erythro-9-(2-hydroxy-3-nonyl)adenine hydrochloride (EHNA). Clin. Immunol. and Immunopath. 1978; 10: 258
   PubMedGoogle Scholar
• Meisel A. D., Natarajan C., Diamond H. S. Effect of adenosine deaminase inhibitors on leucocyte chemotaxis. Clin. Res. 1978; 26: 25A
   Google Scholar
• Duncan G. S., Wolberg G., Zimmerman T. P., Elion G. B. Evidence for a second site of action of erythro-9-(2-hydroxy-3-nonyl)adenine (EHNA) in mouse cytolytic lymphocytes. Fed. Proc. Fed. Am. Soc. Exp. Biol. 1979; 38: 1098
   Google Scholar
• Zuckerman S. H., Kay N. E., Douglas S. D. Effect of adenosine deaminase inhibitors on Fcμ receptor expression in human T-cell culture. Cell. Immunol. 1980; 56: 112
   PubMedGoogle Scholar
• Morita Y., Chiang P. K., Siraganian R. P. Effect of inhibitors of transmethylation on histamine release from human basophils. Biochem. Pharmacol. 1981; 30: 785
   PubMedGoogle Scholar
• Bouchard P., Penningroth S. M., Cheung A., Gagnon C., Bardin C. W. Erythro-9-[3-(2-hydroxynonyl)]adenine is an inhibitor of sperm motility that blocks dynein ATPase and protein carboxymethylase activities. Proc. Natl. Acad. Sci. 1981; 78: 1033
   PubMedGoogle Scholar
• Kaplan A. M., Squire C., Gerrard T. L. Effects of adenosine deaminase inhibitors on induction and mediation of cellular cytotoxicity. Fed. Proc. Fed. Am. Soc. Exp. Biol. 1981; 40: 988
   Google Scholar
• Green R. D. Effects of exogenous adenosine deaminase and erythro-9-(2-hydroxy-3-nonyl)adenine on intracellular cyclic AMP levels in C1300 murine neuroblastoma in tissue culture. Life Sci. 1980; 26: 399
   PubMedGoogle Scholar
• Henderson J. F., Brox L., Zombor G., Hunting D., Lomax C. A. Specificity of adenosine deaminase inhibitors. Biochem. Pharmacol. 1967/1977; 26
   Google Scholar
• Skupp S., Vugrek G., Ayvazian J. H. Effect of erythro-9-(2-hydroxy-3-nonyl)adenine on purine and pyrimidine metabolism in the human peripheral lymphocyte during the early phases of phytohemagglutinin-mediated blastogenesis. Biochem. Pharmacol. 1979; 28: 3323
   PubMedGoogle Scholar
• Lewis A. S. Rabbit brain purine nucleoside phosphorylase: Physical and chemical properties. Inhibition studies with aminopterin, folic acid, and structurally related compounds. Arch. Biochem. Biophys. 1978; 190: 662
   PubMed Web of Science ®Google Scholar
• Lin A. L., Elford H. L. Inhibition of adenosine deaminase activity and ribonucleotide reductase levels in Hela cells. Fed. Proc. Fed. Am. Soc. Exp. Biol. 1979; 38: 496
   Google Scholar
• Zimmerman T. P., Rideout J. L., Wolberg G., Duncan G. S., Elion G. B. 2-Fluoroadenosine 3′:5′-monophosphate: A metabolite of 2-fluoroadenosine in mouse cytotoxic lymphocytes. J. Biol. Chem. 1976; 251: 6757
   PubMedGoogle Scholar
• Zimmerman TP., Deeprose R. D., Wolberg G., Duncan G. S. Potentiation by homocysteine of adenosine-stimulated elevation of cellular adenosine 3′.5′-monophosphate. Biochem. Pharmacol. 1979; 28: 2375
   PubMedGoogle Scholar
• Zimmerman T. P., Schmitges C. J., Wolberg G., Deeprose R. D., Duncan G. S., Cuatrecasas P., Elion G. B. Modulation of cyclic AMP metabolism by S-adenosylhomocysteine and S-3-deazaadenosylhomocysteine in mouse lymphocytes. Proc. Natl. Acad. Sci. 1980; 77: 5639
   PubMed Web of Science ®Google Scholar
• Wolberg G., Hiemstra K., Burge J. J., Singler R. C. Reversible inhibition of lymphocyte-mediated cytolysis by dimethyl sulfoxide (DMSO). J. Immunol. 1973; 111: 1435
   PubMedGoogle Scholar
• Zimmerman T. P., Wolberg G., Duncan G. S. Inhibition of lymphocyte-mediated cytolysis by 3-deazaadenosine: Evidence for a methylation reaction essential to cytolysis. Proc. Natl. Acad. Sci. 1978; 75: 6220
   PubMedGoogle Scholar
• Van Haverbeke D. A., Brown P. R. Optimization of a procedure for extraction of nucleotides from plasma and erythrocytes prior to HPLC analysis. J. Liq. Chromatogr. 1978; 1: 507
   Google Scholar
• O'Dea R. F., Viveros O. H., Axelrod J., Aswani kumar S., Schiffmann E., Corcoran B. A. Rapid stimulation of protein carboxymethylation in leukocytes by a chemo-tactic peptide. Nature 1978; 272: 462
   PubMed Web of Science ®Google Scholar
• Matsumoto S. S., Raivio K. O., Seegmiller J. E. Adenine nucleotide degradation during energy depletion in human lymphoblasts. J. Biol. Chem. 1979; 254: 8956
   PubMed Web of Science ®Google Scholar
• Whisnant C. C., Singer K. H., Amos D. B. Interaction of cytotoxic T lymphocytes with target cells. I. Specific inhibition by detergent-solubilized, partially purified mouse histocompatibility antigens. J. Immunol. 1978; 121: 2253
   PubMedGoogle Scholar
• Wolberg G., Zimmerman T. P., Hiemstra K., Winston M., Chu L. C. Adenosine inhibition of lymphocyte-mediated cytolysis: Possible role of cyclic adenosine monophosphate. Science 1975; 187: 957
   PubMedGoogle Scholar
• Martz E. Early steps in specific tumor cell lysis by sensitized mouse T lymphocytes: I. Resolution and characterization. J. Immunol. 1975; 115: 261
   PubMedGoogle Scholar
• Berke G., Sullivan K. A., Amos B. Rejection of ascites tumor allografts. II. A pathway for cell-mediated tumor destruction in vitro by peritoneal exudate lymphoid cells. J. Exp. Med. 1972; 136: 1594
   PubMedGoogle Scholar
• Borchardt R. T. S-Adenosyl-L-methionine-dependent macromolecule methyltransferases: Potential targets for the design of chemotherapeutic agents. J. Med. Chem. 1980; 23: 347
   PubMedGoogle Scholar
• Zimmerman T. P., Schmitges C. J., Wolberg G., Deeprose R. D., Duncan G. S. Inhibition of cyclic AMP phosphodiesterase by 5′-deoxy-5′-S-isobutylthioadenosine at biologically active concentrations of drug. Life Sciences 1981; 28: 647
   PubMed Web of Science ®Google Scholar
• Wolberg G., Zimmerman T. P., Duncan G. S., Singer K. H., Elion G. B. Inhibition of lymphocyte-mediated cytolysis by adenosine analogs: Biochemical studies concerning mechanism of action. Biochem. Pharmacol. 1978; 27: 1487
   PubMed Web of Science ®Google Scholar
• Atkinson J. P., Wedner H. J., Parker C. W. Two novel stimuli of cyclic adenosine 3′,5′-monophosphate (cAMP) in human lymphocytes. J. Immunol. 1975; 115: 1023
   PubMedGoogle Scholar
• Virji M., Stevenson G. T. Antibody-induced changes in levels of cyclic adenosine monophosphate in leukaemic lymphocytes. Br. J. Cancer 1979; 39: 434
   PubMedGoogle Scholar
• Krishnaraj R., Talwar G. P. Role of cyclic AMP in mitogen induced transformation of human peripheral leukocytes. J. Immunol. 1973; 111: 1010
   PubMed Web of Science ®Google Scholar
• Lyle L. R., Parker C. W. Cyclic adenosine 3′,5′-mono-phosphate responses to concanavalin A in human lymphocytes. Evidence that the response involves specific carbohydrate receptors on the cell surface. Biochemistry 1974; 13: 5415
   PubMedGoogle Scholar
• Jackowski S., Sha'afi R.I. Response of adenosine cyclic 3′,5′-monophosphate level in rabbit neutrophils to the chemotactic peptide formyl-methionyl-leucyl-phenyl-alanine. Mol. Pharmacol. 1979; 16: 473
   PubMedGoogle Scholar
• Smolen J. E., Korchak H. M., Weissmann G. Increased levels of cyclic adenosine-3′,5′-monophosphate in human polymorphonuclear leukocytes after surface stimulation. J. Clin. Invest. 1980; 65: 1077
   PubMedGoogle Scholar
• Sullivan T. J., Parker K. L., Kulczycki A., Jr., Parker C. W. Modulation of cyclic AMP in purified rat mast cells. III. Studies on the effects of concanavalin A and anti-IgE on cyclic AMP concentrations during histamine release. J. Immunol. 1976; 117: 713
   PubMedGoogle Scholar
• Holgate S. T., Lewis R. A., Austen K. F. The role of cyclic nucleotides in mast cell activation and secretion, in Progress in Immunology IV. Fourth International Congress of Immunology, M. Fougereau, J. Dausset. Academic Press, London 1980; 846
   Google Scholar
• Berke G. Interaction of cytotoxic T lymphocytes and target cells. Prog. Allergy 1980; 27: 69
   PubMedGoogle Scholar
• Zimmerman T. P., Wolberg G., Duncan G. S. Metabolism of tubercidin and formycin to their 3′:5′-cyclic nucleotides in mammalian cells. J. Biol. Chem. 1978; 253: 8792
   PubMedGoogle Scholar